1. Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas.
- Author
-
Patel RS, Dhamne CA, Gopinathan A, Kumar N, and Kumar N
- Subjects
- Adolescent, Bone Cysts, Aneurysmal diagnosis, Calcitonin therapeutic use, Humans, Magnetic Resonance Imaging, Male, Methylprednisolone therapeutic use, Tomography, X-Ray Computed, Bone Cysts, Aneurysmal drug therapy, Bone Density Conservation Agents therapeutic use, Cervical Atlas pathology, Denosumab therapeutic use
- Abstract
Purpose: Aneurysmal bone cysts (ABCs) of spine are conventionally treated with en-bloc resection or intralesional excision/curettage and reconstruction or filling of defects with bone cement. For the treatment of upper cervical ABCs, en-bloc resections are often not desirable considering the risk/benefit ratio while the risk of recurrence after intralesional excision is high. Hence, alternative management options are often necessary. We describe our clinical experience with one such treatment alternative-denosumab for the treatment of ABC of Atlas., Methods and Results: We present a case of 16-year-old boy who presented with neck pain and restriction of neck movements. A large lytic lesion with multiple fluid-fluid interfaces involving vertebral arch of atlas was identified on further imaging. There was destruction of right lateral mass and the lesion was found encasing the right vertebral artery. Core needle biopsy confirmed the diagnosis of ABC. With no visible CT response after first session of intra-lesional injection of Calcitonin and Methylprednisolone, the patient was treated with denosumab (120 mg SC once-a-month) for a period of 12 months. His symptoms resolved within 7 months of onset of treatment and serial CT scans over 12-month treatment period showed complete ossification of the lesion. Further there was no evidence of recurrence at 12 months after completion of treatment., Conclusion: Our case report contributes to the accruing evidence on the effectiveness of denosumab for the treatment of spinal ABCs. However, long-term safety, risk of recurrence, optimal duration of treatment and consistency of denosumab are yet to be determined.
- Published
- 2018
- Full Text
- View/download PDF